BOSTON–(BUSINESS WIRE)–GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the appointment of Bruce Beutel, PhD to its Board of Directors and its upcoming participation and activity during J.P. Morgan Health Care Week in January 2022.
GRObio appointed Bruce Beutel, PhD to its Board of Directors. Dr. Beutel is an expert in novel therapeutics and platform research, business development, and company creation. Over the course of his career, he has focused on strategy, vision, team building and value creation at the interface of science and business, particularly for emerging biotechnology companies. Dr. Beutel has held several C-level roles in multiple biotechnology companies including founding Chief Operating Officer and Chief Business and Strategy Officer at Dewpoint Therapeutics. He also has served in leadership roles at both Abbott and Merck. Dr. Beutel now serves as Venture Partner with Qiming Venture Partners USA. Dr. Beutel received his PhD in Molecular Biology from University of Wisconsin–Madison.
“We are thrilled to have Bruce join our Board of Directors. His long-standing experience in building successful platform biotechnology companies will help ensure GRObio’s technology reaches its greatest potential,” said Daniel J. Mandell, PhD, Co-Founder and Chief Executive Officer of GRO Biosciences. “Bruce’s depth of experience from founding and leading biotechnology companies, to serving in business development, operations and strategy roles will be a great asset to GRObio as we continue to advance our platform, pipeline and partnerships.”
GRObio at JPM
GRObio senior leadership will attend the J.P. Morgan Health Care Conference from January 10 – 14 and will participate in in-person meetings as well as virtual meetings via the Biotechnology Innovation Organization (BIO) Partnering platform.
To arrange a meeting with GRObio leadership, contact Tad Stewart, GRObio’s Chief Business Officer via email at firstname.lastname@example.org.
About GRO Biosciences
GRO Biosciences (“GRObio”) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Company’s NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by Dr. George Church of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.
Investor & Partnering Contact: